Share chart Bolt Biotherapeutics, Inc.
Extended chart
Simple chart
About
Bolt Biotherapeutics, Inc., иммуноонкологическая компания, работающая на клинической стадии, занимается открытием, разработкой и коммерциализацией фармацевтических продуктов. Компания разрабатывает BDC-1001, рецептор 2 эпидермального фактора роста человека (HER2) для лечения пациентов с HER2-экспрессирующими солидными опухолями, включая опухоли с низким содержанием HER2; и BDC-2034, программа карциноэмбриональных антигенов для колоректального, немелкоклеточного рака легких, поджелудочной железы и молочной железы.
More details| P/S | 132.98 |
|---|---|
| EV/EBITDA | 0.8055 |
| EBITDA | -0.0306 |
| Цена ао | 0.6901 |
| Сайт | http://www.boltbio.com |
| P/BV | 0.6699 |
| Число акций ао | 0.03781 млрд |
| Выручка | 0.000215 |
| Див.доход ао | 0 |
| ISIN | US0977021049 |
| Валюта | usd |
| IPO date | 2021-02-05 |
| Sector | Health Care |
| Industry | Biotechnology |
| Валюта отчета | usd |
| Change price per day: | +7.33% (0.643) |
|---|---|
| Change price per week: | +3% (0.67) |
| Change price per month: | +10.29% (0.6257) |
| Change price per 3 month: | -8% (0.7501) |
| Change price per half year: | -37.83% (1.11) |
| Change price per year: | -32.34% (1.02) |
| Change price per 3 year: | -93.31% (10.31) |
| Change price per year to date: | -23.24% (0.899) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Tang Capital Management, LLC | 3652244 | 9.58 |
| Vivo Capital, LLC | 3521291 | 9.24 |
| Sofinnova Investments, Inc. | 2754437 | 7.22 |
| Citadel Advisors Llc | 2458958 | 6.45 |
| Pivotal bioVenture Partners Investment Advisor, LLC | 1891467 | 4.96 |
| Newtyn Management, LLC | 1553535 | 4.07 |
| Orbimed Advisors LLC. | 1541000 | 4.04 |
| Nan Fung Group Holdings Limited | 1166952 | 3.06 |
| Samsara BioCapital, LLC | 1049153 | 2.75 |
| Vanguard Group Inc | 931129 | 2.44 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.00481 | 43.316995205115 | 1.54048 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. William P. Quinn | CEO, CFO, President, Secretary & Director | 594.56k | 1971 (53 years) |
| Mr. Wesley Burwell | VP & Head of Human Resources | N/A | |
| Mr. Grant Yonehiro C.F.A., M.B.A. | Chief Operating Officer | 544.71k | 1964 (60 years) |
| Dr. Nathan Ihle Ph.D. | Senior Vice President of Pharmaceutical Operations | N/A | |
| Ms. Sarah Nemec | VP of Finance & Principal Accounting Officer | 1976 (48 years) | |
| Dr. Dawn Colburn BCOP, Pharm.D. | Senior Vice President of Clinical Development | ||
| Dr. Michael N. Alonso Ph.D. | Senior Vice President of Research |
Address: United States, Redwood City, CA , 900 Chesapeake Drive - open in Google maps, open in Yandex maps
Website: http://www.boltbio.com
Website: http://www.boltbio.com
